key: cord-0981948-rhccjxe4
authors: Perrin, Peggy; Collongues, Nicolas; Baloglu, Seyyid; Bedo, Dimitri; Bassand, Xavier; Lavaux, Thomas; Gautier‐Vargas, Gabriela; Keller, Nicolas; Kremer, Stéphane; Fafi‐Kremer, Samira; Moulin, Bruno; Benotmane, Ilies; Caillard, Sophie
title: Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19
date: 2020-08-27
journal: Eur J Neurol
DOI: 10.1111/ene.14491
sha: 943da923af4799e886e3a691280c8be3fefdf6d7
doc_id: 981948
cord_uid: rhccjxe4

BACKGROUND: Neurological manifestations in coronavirus disease (COVID)‐2019 may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors for neurological complications. However, the lack of insight into their pathogenesis, particularly with respect to the role of the cytokine release syndrome (CRS), is currently hampering effective therapeutic interventions. METHODS: In this longitudinal study, we sought to describe the neurological manifestations of patients with COVID‐19 and gain pathophysiological insights especially with respect to the CRS. Extensive clinical, laboratory, and imaging phenotyping was performed in five patients admitted to our renal unit. RESULTS: Neurological presentation included confusion, tremor, cerebellar ataxia, behavioral alterations, aphasia, pyramidal syndrome, coma, cranial nerve palsy, dysautonomia, and central hypothyroidism. Neurological disturbances were remarkably accompanied by laboratory evidence of CRS. SARS‐CoV‐2 was undetectable in the cerebrospinal fluid (CSF). Hyperalbuminorrachia and increased levels of the astroglial protein S100B were suggestive of blood‐brain barrier (BBB) dysfunction. Brain MRI findings comprised evidence of acute leukoencephalitis (n = 3, of whom one with a hemorrhagic form), cytotoxic edema mimicking ischemic stroke (n = 1), or normal results (n = 2). Treatment with corticosteroids and/or intravenous immunoglobulins was attempted – resulting in rapid recovery from neurological disturbances in two cases. SARS‐CoV2 was undetectable in 88 of the 90 patients with COVID‐19 who underwent RT‐PCR testing of CSF. CONCLUSIONS: Patients with COVID‐19 can develop neurological manifestations that share clinical, laboratory, and imaging similarities with those of chimeric antigen receptor‐T cell‐related encephalopathy. The pathophysiological underpinnings appear to involve CRS, endothelial activation, BBB dysfunction, and immune‐mediated mechanisms.

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can be complicated by neurological manifestations that have an adverse impact on morbidity and mortality [1] [2] [3] . A study from China reported preliminary evidence that neurological manifestations may be present in up to 36% of hospitalized cases [1] . Severe neurological manifestations occurred in 10% of patients during their hospital stay, with severe disease and uremia acting as potential risk factors [1] . Unfortunately, the clinical detection of neurological symptoms in patients with COVID-19 remains challenging because of the severity of concomitant respiratory and systemic manifestations. Moreover, the lack of insight into the presentation and pathogenesis of neurological complications is currently hampering effective therapeutic interventions [3] .

Similar to other coronaviruses, SARS-CoV-2 theoretically has the potential to penetrate into the central nervous system (CNS) through hematogenous or retrograde neuronal routes [4] . However, the question as to whether SARS-CoV-2 may cause neurological manifestations through a direct neuropathic effects or by promoting a hyperinflammatory reaction mounted by the host's immune system in the form a cytokine release syndrome (CRS) remains to be established [5] . Noteworthy is also the observation that high serum levels of interleukin (IL)-6 are a strong predictor of mortality in patients with COVID-19 [6] .

In this longitudinal study conducted in a renal unit, we describe five patients with severe COVID-19 who presented severe neurological manifestations. Extensive clinical, laboratory, imaging phenotyping was performed to gain pathophysiological insights that may guide clinical decisionmaking -especially with respect to the CRS.

Between March 9 and April 9, 2020, a total of 2284 patients were hospitalized with COVID-19 at the Strasbourg University Hospital (Strasbourg, France). Of them, 328 were directly admitted to the Intensive Care Unit and 58 to our renal unit. The distribution of the underlying disorders in our 58 patients was as follows: previous kidney transplantation (n = 37), end-stage renal disease (n =

This article is protected by copyright. All rights reserved 16) , acute kidney injury (n = 4), and hyponatremia (n = 1). Seven cases (12.7%) developed severe neurological manifestations. In the context of clinical care, five of them underwent an extensive laboratory and imaging characterization. The remaining two (presenting with coma and seizures) were excluded because of the lack of extensive laboratory and MRI data. SARS-CoV-2 infection was confirmed in all cases by RT-PCR assays targeting the RNA-dependent RNA polymerase (RdRp) viral gene from nasopharyngeal swab specimens. According to current French laws, ethical approval for retrospective studies conducted in the context of clinical care can be waived.

All of the five patients underwent an extensive clinical work-up aiming at excluding other causes of neurological impairment -such as alcohol or drug intoxication, metabolic disorders, hypoxemia, thiamine or vitamin B12 deficiencies, epilepsy, hypothermia, sepsis, antibiotic overdosage, hypercapnic encephalopathy, hepatic encephalopathy, and CNS infections. All patients underwent lumbar puncture to screen for the presence of SARS-CoV-2 in the cerebrospinal fluid (CSF). When serum laboratory findings showed signs of CRS, patients received dexamethasone (20 mg/day for five days in all cases, followed by individualized dosing). [7] Antibiotic and antithrombotic prophylaxis was offered to all participants.

As of the beginning of the COVID-19 pandemic in France, we conducted as an integral part of our clinical practice longitudinal assessments of numerous laboratory markers in an effort to identify the occurrence of CRS -defined by a peak in levels of proinflammatory molecules (IL-6, Creactive protein, ferritin) and indices of cytolysis (e.g., lactate dehydrogenase). Markers of inflammation, CRS, cell lysis, coagulation, thrombotic microangiopathy, were measured. Levels of serum thyroid hormones were also assessed. Serum levels of S100B protein -an established astroglial marker [8] -were quantified on a Roche e411 analyzer (F. Hoffmann-La Roche AG, Basel, Switzerland), whereas IL-6 was measured with a chemiluminescent immunoassay (Lumipulse G600 II; Fujirebio, Tokyo, Japan) [9].

To investigate whether SARS-CoV-2 was detectable in the CSF, RT-PCR assays were conducted according to current guidelines (Institut Pasteur, Paris, France; World Health Organization

This article is protected by copyright. All rights reserved technical guidance). The threshold limit of detection was 10 copies per reaction. Biochemical and immunological analysis of CSF were also performed.

All patients underwent brain magnetic resonance imaging (MRI) on a 3-Tesla MRI scanner. The following protocols were applied: three-dimensional T1-weighted spin-echo, three-dimensional fluid-attenuated inversion recovery (FLAIR; both with and without gadolinium), diffusionweighted imaging (DWI), susceptibility-weighted imaging (SWI), and two-dimensional FLAIR post-contrast imaging.

Five patients with severe COVID-19 were included in the study: a 71-year-old woman (case 1), 64-year-old man (case 2), a 53-year-old woman (case 3), a 51-year-old man (case 4), and a 67year-old man (case 5). No patient had a known history of neurological disease or previous neurological manifestations. Case 3 and 4 had severe COVID-19-related acute kidney injury. Table 1 summarizes the general characteristics, clinical features, neurological disturbances, MRI findings, EEG results, treatment approaches, and outcomes of the five study patients. Neurological presentation included confusion (n = 5), tremor (n = 5), cerebellar ataxia (n = 5), behavioral alterations (n = 5), aphasia (n = 4), pyramidal syndrome (n = 4), coma (n = 2), cranial nerve palsy (n = 1), and central hypothyroidism (n = 3). Case 1 died of coma and secondary infection.

A timeline of the neurological and respiratory course according to symptom onset is shown in Figure 1 A, B, C, D, and E. Neurological disturbances occurred in the second week after COVID-19 onset (24−48 h after respiratory degradation) in cases 1, 2, and 5. In cases 2 and 3, the exact date at onset of neurological signs was not assessable because of the patients' critical conditions requiring mechanical ventilation; therefore, their assessment was conducted following extubation.

This issue highlights the paramount importance of biomarkers for early identification of neurological disturbances. Neurological disorders may also play a role in the onset of agitation and may result in a prolonged ventilation time. Brain MRI findings were heterogeneous and included evidence of acute leukoencephalitis (cases 1, 2, and 4; the latter with a hemorrhagic form),

This article is protected by copyright. All rights reserved cytotoxic edema mimicking an ischemic stroke (case 2), and normal results (cases 3 and 5; Figure   2 ).

The temporal course of CRS biomarkers and viral loads is presented in Figure 3 A, B, C, D, and E.

Neurological manifestations occurred simultaneously with the peak in CRS serum markers (i.e., CRP, IL-6 and LDH) in cases 1, 2, and 5. The peak in CRS markers for cases 2 and 3 occurred while the patients were under mechanical ventilation and serve as potential biomarkers. Serum levels of the astroglial marker, S100B protein, were increased at the time of CRS -reflecting an increased permeability of the blood-brain barrier (BBB) -and returned to their reference range when neurological symptoms and signs of hyperinflammation regressed ( Figure 4 ). Detailed laboratory data are reported in Table 1S . Circulating anticoagulant was detected in cases 1, 2, and 4 but not in case 5. Antiphospholipid antibodies were present in case 1 but undetectable in the remaining four cases. Antinuclear antibodies were assessed in cases 2 and 5 and found to be positive. Serum total complement as well as C3 and C4 were within the reference ranges.

SARS-CoV-2 was undetectable in the CSF for all patients ( Figure 3 ). According to data from our Department of Virology, SARS-Cov-2 was undetectable in 88 of the 90 patients with COVID-19 who underwent RT-PCR testing of CSF (personal communication).

CSF/serum albumin index was measured in four patients and found to be increased in threesuggesting the presence of BBB dysfunction. Neither CSF cells nor IgG intrathecal synthesis were evident. A CSF increase in IL-6 levels was observed in two patients at the time of lumbar puncture. With the only exception of case 5, oligoclonal bands were undetectable. Antineuronal antibodies were absent in all patients (Table 2S) .

The treatment approaches and outcomes of the five study patients are shown in Figure 1 .

Therapeutic attempts with corticosteroids and intravenous immunoglobulins are described below.

This article is protected by copyright. All rights reserved Corticosteroids were given fourteen days after symptom onset to tackle CRS, followed by a temporary improvement with regression of neurologic disturbances ( Figure 1A) . Unfortunately, the patient experienced a second worsening of her neurological state on day 19 (Glasgow Coma

Two days after admission, the patient was switched on hemodialysis in an effort to decrease blood urea nitrogen but no improvement in neurological conditions was observed (ultimately excluding uremic encephalopathy). Further deterioration occurred on day 13, when he presented with a diffuse pyramidal syndrome, mixed fluent and non-fluent aphasia, anterograde amnesia, cerebellar ataxia, a dysexecutive syndrome, and dysautonomia. Following a 5-day course of dexamethasone, an improvement of both consciousness and respiratory conditions was observed ( Figure 1B ). Four days after withdrawal of dexamethasone, there was a further neurological relapse with appearance of Cheyne-Stokes breathing (GCS = 10). Because of the life-threatening neurological conditions, dexamethasone was reintroduced along with intravenous immunoglobulins (IVIg) for 5 days. A complete and rapid clinical response was observed. A second cycle of IVIg has been planned.

The neurological state spontaneously and gradually improved until discharge on day 40 after symptom onset.

Neurological disturbances gradually and spontaneously regressed with recovery of orientation, memory function and motor function. Although ataxia and nystagmus improved partially, pyramidal syndrome and affective symptoms persisted on discharge on day 35.

A 67-year-old man with a history of KT was admitted on day 6 with moderate dyspnea.

Mycophenolate mofetil was withdrawn followed by administration of hydroxychloroquine.

On day 9, worsening of respiratory conditions with signs of CRS was evident -prompting dexamethasone administration. On day 11, he developed acute neurologic alterations consisting of bilateral reduced visual acuity, horizontal diplopia on the left side, predominant right cerebellar Accepted Article ataxia, tetrapyramidal syndrome, and personality change. Visual assessment revealed 7/10 right visual acuity drop, 1/10 left visual acuity drop in a previously amblyopic eye, a left abduction deficiency, and a left cervical stiff neck caused by sixth nerve palsy. Pupillary light reflexes and fundus examination were normal. Signs of neurological deterioration were paralleled by laboratory evidence of CRS. Upon treatment with methylprednisolone (500 mg/day for three days), both neurological disturbances and respiratory symptoms improved. Dexamethasone was subsequently given for ten days to tackle CRS ( Figure 1E ). On day 60, all neurological signs have regressed except slight palsy of left nerve VI. symptoms onset, i.e., simultaneously with the worsening of respiratory conditions. The systemic presentation was reflective of clinical symptoms related to the CRS (i.e., fever, headache, myalgia, occasional rash, respiratory failure, and -in some cases -multiorgan failure) [11] .

Second, the laboratory work-out demonstrated that SARS-CoV-2 was undetectable in the CSF in our patients (as it was in 98% of patients who performed this test in our hospital). Signs and symptoms of CNS impairment were accompanied by evidence of CRS in serum samples with marked elevation of serum IL-6. Third, we found evidence of an increased BBB permeability as attested by the presence of hyperalbuminorrachia. Moreover, elevation of serum levels of the S100B protein -an astroglial marker -was found to occur simultaneously with CRS. Finally, MRI findings were heterogeneous and included evidence of acute leukoencephalitis (n = 3, of whom one with a hemorrhagic form), cytotoxic edema mimicking an ischemic stroke (n = 1), or

This article is protected by copyright. All rights reserved normal results (n = 2). Notably, MRI findings are frequently normal both in influenza-related acute encephalitis and autoimmune encephalitis [12] .

Our findings of CRS-associated neurological disturbances in COVID-19 expand previous observations showing that hyperinflammation is associated with deterioration of respiratory function and death [5] , [6] . Our data may have relevant implications with respect to clinical management. Because a reliable detection of neurological symptoms may be unfeasible in patients on ventilation support, laboratory evidence of CRS should alert clinicians about a potential risk of CNS involvement. Notably, the onset of neurological manifestations was also paralleled by an increase in serum levels of S100B protein (reflecting an increased BBB permeability) [8] .

Elevated serum S100B levels have been previously reported in other acute encephalitis and immune effector cell neurotoxicity syndrome (ICANS) [13] , [14] , [15] .

CRS is a potentially fatal complication of different infectious (e.g., influenza, SARS, Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis) and noninfectious (e.g., multiple organ dysfunction syndrome, multiple sclerosis) diseases. Moreover, it can have a iatrogenic origin during the course of T and B lymphocyte engaging therapies like chimeric antigen receptor (CAR)-T-cell immunotherapy, rituximab, and immune check-point inhibitors [16] , [11] . CRS is triggered by an initial release of proinflammatory cytokines from activated T and/or B cells; this event in turn activates bystander immune cells and endothelial cells to produce proinflammatory molecules. Engagement of other immune cells follows in the context of a self-perpetuating positive feedback loop. In this scenario, excess production of IL-6 from activated macrophages is a key event. CRS-driven neurological disturbances have been described for the first time following CAR-T cell therapy and termed ICANS. Remarkably, the clinical, laboratory, and imaging features of severe ICANS closely resemble those shown by the five patients with COVID-19 described in our series [17] , [18] , [13] . Brain MRI in ICANS revealed the presence of acute T2/FLAIR hyperintensities suggestive of interstitial edema of varying severity and small (mmscale) ischemic strokes [13] . One of our cases had a lesion in the splenium of the corpus callosum -a finding in accordance with previous data reported in ICANS [19] and encephalitis complicating acute viral infections (e.g., influenza and mumps) [12] . In ICANS, hemorrhagic forms (similar to the findings of patient 4 in our series) have been described [18] . More importantly, proinflammatory cytokines like IL-6 have been shown to lead to endothelial damage and BBB dysfunction in this clinical entity [18] , [13] .

This article is protected by copyright. All rights reserved All of these findings, coupled with the existing evidence, allow offering a pathophysiological model ( Figure 5 ) according to which COVID-19-associated neurological manifestations are driven by CRS and consequent immune response. Certain neurological complications of COVID-19 may be caused by endothelial activation with subsequent increased BBB permeability, edema, [20] and penetration of proinflammatory cytokines that can activate microglial cells in the CNS. The resulting neuroinflammatory response may yield to reactive gliosis accompanied by infiltration of CD68+ monocytes/macrophage [21] and release of S100B protein. This pathophysiological model is in accordance with an autopsy report in COVID-19 showing a range of white matter pathology with an anatomical distribution compatible with MRI lesions observed in our patients (i.e., subcortical areas, corpus callosum, middle cerebellar peduncle) and the lack of typical features of viral encephalitis. Rare neocortical microscopic organizing infarcts were also identified, suggesting a vascular origin followed by secondary myelin loss [22] .

In keeping with our management strategies to tackle CRS, three of our patients with neurological disturbances received corticosteroids and one IVIg with improvement. This in accordance with two case of encephalopathy in COVID-19 with improvement after steroid [23] , and IVIg [24] .

Blockade of IL-6 with tocilizumab -an anti-IL-6 receptor (IL-6R) monoclonal antibody -has been also approved to treat CRS complicating CAR-T cell therapy in the absence of neurological manifestations. Although tocilizumab may be effective against CRS, this molecule is not clinically useful to treat neurotoxicity in the context of CAR-T cell therapy and can even exacerbate this condition [11] , [13] .This paradoxical effect may be explained by the transient rise in serum IL-6 observed following tocilizumab administration and by the poor penetration of this antibody into the cerebrospinal fluid [25] .

Administration of IVIg during the early course of severe COVID-19 may improve clinical outcomes through their immunomodulatory effects against the self-perpetuating positive inflammatory loop typical of CRS [18, 19] . Interestingly, high-dose IVIg may reduce in vitro and in vivo production of IL-6 in other infectious or autoimmune diseases [20, 21] . In the current series, a rapid recovery was observed following administration of IVIg (0.4 g per kg of weight per day for five consecutive days) in case 2.

Our findings need to be interpreted in the context of some limitations. Notably, this is a case series 

This article is protected by copyright. All rights reserved [20] . In turn, an altered BBB permeability may lead to edema and even red blood cells extravasation (potentially accounting for the hemorrhagic form of acute leukoencephalitis observed in case #4). This sequence of events closely resembles those occurring in immuneeffector cell neurotoxicity syndrome [18] . Proinflammatory cytokines can leak through a dysfunctional BBB, ultimately activating microglial cells (brain tissue-resident macrophages).

This may in turn lead to a secondary inflammatory response in the macroglia accompanied by the release of S100B, an astroglial protein reflecting both glial activation and BBB dysfunction. The resulting neuroinflammatory response can yield to reactive gliosis accompanied by infiltration of

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurologic Features in Severe SARS-CoV-2 Infection

Neurology A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details

Nervous system involvement after infection with COVID-19 and other coronaviruses

UK COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia

The S100B story: from biomarker to active factor in neural injury

Lumipulse G600 II: analytical evaluation and comparison with three other laboratory analyzers. Clinical Chemistry and Laboratory Medicine (CCLM) 2020, 0

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection

Acute encephalitis in immunocompetent adults

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy

Glial S100B is elevated in serum across the spectrum of

West Nile virus infection

Prognostic value of brain injury biomarkers in acute encephalitis/encephalopathy

Into the eye of the cytokine storm. Microbiol

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Molecular pathophysiology of cerebral edema

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

Steroid-responsive encephalitis in Covid-19 disease

Evolution and resolution of brain involvement associated with SARS-CoV2 infection: A close Clinical -Paraclinical follow up study of a case

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

This article is protected by copyright. All rights reserved